SK286040B6 - Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín - Google Patents

Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín Download PDF

Info

Publication number: SK286040B6
Authority: SK; Slovakia
Prior art keywords: pharmaceutical composition; trifluoromethylphenyl; donepezil; ylethyl; tacrine
Prior art date: 1997-11-14

Application number

SK711-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK7112000A3 (en

Inventor

Jean-Pierre Maffrand

Philippe Soubrie

Jean-Paul Terranova

Original Assignee

Sanofi - Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-14

Filing date

1998-11-09

Publication date

2008-01-07

1997-11-14 Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr

1997-11-14 Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr

1998-11-09 Application filed by Sanofi - Aventis filed Critical Sanofi - Aventis

2000-10-09 Publication of SK7112000A3 publication Critical patent/SK7112000A3/sk

2008-01-07 Publication of SK286040B6 publication Critical patent/SK286040B6/sk

Links

ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title claims abstract description 28
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
229960001685 tacrine Drugs 0.000 title claims abstract description 14
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 title claims abstract description 14
229960003530 donepezil Drugs 0.000 title claims abstract description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title description 2
239000004480 active ingredient Substances 0.000 claims abstract description 22
WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 claims abstract description 14
239000003814 drug Substances 0.000 claims abstract description 6
206010012289 Dementia Diseases 0.000 claims description 10
150000001875 compounds Chemical class 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 5
239000000203 mixture Substances 0.000 abstract description 11
208000024827 Alzheimer disease Diseases 0.000 abstract description 3
206010039966 Senile dementia Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
241000700159 Rattus Species 0.000 description 5
239000000544 cholinesterase inhibitor Substances 0.000 description 5
238000002636 symptomatic treatment Methods 0.000 description 5
108010025020 Nerve Growth Factor Proteins 0.000 description 4
230000000694 effects Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 description 4
-1 2-naphth-2-ylethyl Chemical group 0.000 description 3
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
230000003902 lesion Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
229960004528 vincristine Drugs 0.000 description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
230000000508 neurotrophic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004036 social memory Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
IFYKRMQORZOMNY-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCNCC=2)=C1 IFYKRMQORZOMNY-UHFFFAOYSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940039856 aricept Drugs 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000015654 memory Effects 0.000 description 1
230000006386 memory function Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
239000002664 nootropic agent Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SK711-2000A 1997-11-14 1998-11-09 Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín SK286040B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9714324A FR2771006B1 (fr)	1997-11-14	1997-11-14	Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr)	1997-11-14	1997-11-14	Association de principes actifs pour le traitement de la demence senile du type alzheimer
PCT/FR1998/002384 WO1999025363A1 (fr)	1997-11-14	1998-11-09	Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer

Publications (2)

Publication Number	Publication Date
SK7112000A3 SK7112000A3 (en)	2000-10-09
SK286040B6 true SK286040B6 (sk)	2008-01-07

Family

ID=26233932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK711-2000A SK286040B6 (sk)	1997-11-14	1998-11-09	Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín

Country Status (27)

Country	Link
EP (1)	EP1030671A1 (fr)
JP (1)	JP2001523642A (fr)
KR (1)	KR100599350B1 (fr)
CN (1)	CN1243540C (fr)
AU (1)	AU743228B2 (fr)
BG (1)	BG64819B1 (fr)
BR (1)	BR9814035A (fr)
CA (1)	CA2309966A1 (fr)
CO (1)	CO4980891A1 (fr)
DZ (1)	DZ2649A1 (fr)
EA (1)	EA003255B1 (fr)
EE (1)	EE04235B1 (fr)
HU (1)	HUP0100098A3 (fr)
ID (1)	ID24933A (fr)
IL (2)	IL136122A0 (fr)
IS (1)	IS5482A (fr)
MY (1)	MY120461A (fr)
NO (1)	NO20002450L (fr)
NZ (1)	NZ504420A (fr)
OA (1)	OA11464A (fr)
PL (1)	PL194597B1 (fr)
SA (1)	SA98190747B1 (fr)
SK (1)	SK286040B6 (fr)
TR (1)	TR200001262T2 (fr)
TW (1)	TW585766B (fr)
UY (1)	UY25247A1 (fr)
WO (1)	WO1999025363A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE041842T2 (hu)	2002-06-14	2019-05-28	Toyama Chemical Co Ltd	Gyógyászati készítmény agymûködés javítására
JP2005534710A (ja) *	2002-08-07	2005-11-17	ノバルティスアクチエンゲゼルシャフト	Ａｐｏｅ遺伝子型を基準とした痴呆を処置するための方法
CN1520818A (zh) *	2003-02-09	2004-08-18	ɽ��Ҷ��Ȼҩ��о��޹�˾	治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
MX2007007836A (es)	2004-12-27	2007-08-20	Eisai R&D Man Co Ltd	Metodo para estabilizar un farmaco anti-demencia.
RU2692258C2 (ru)	2014-01-31	2019-06-24	Когнишн Терапьютикс, Инк.	Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da)	2017-05-15	2026-03-02	Cognition Therapeutics Inc	Sammensætninger til behandling af neurogenerative sygdomme
KR102224918B1 (ko)	2018-03-20	2021-03-09	(주)인벤티지랩	도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (fr) *	2018-03-20	2019-09-26	(주)인벤티지랩	Procédé de préparation de composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, et composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, préparée par le procédé de préparation
CN109265391B (zh) *	2018-11-13	2021-11-19	枣庄学院	联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2662355B1 (fr) *	1990-05-22	1994-11-10	Sanofi Sa	Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) *	1991-02-14	1995-09-26	The Mount Sinai School Of Medicine Of The City Of New York	Method and composition for the treatment of apathy-amotivation syndrome
ES2244968T3 (es) *	1995-03-06	2005-12-16	Interneuron Pharmaceuticals Incorporated	Reduccion del volumen de infarto usando citocolina.
FR2736053B1 (fr) *	1995-06-28	1997-09-19	Sanofi Sa	Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

1998
- 1998-10-26 CO CO98062479A patent/CO4980891A1/es unknown
- 1998-10-28 TW TW087117874A patent/TW585766B/zh not_active IP Right Cessation
- 1998-11-09 TR TR2000/01262T patent/TR200001262T2/xx unknown
- 1998-11-09 WO PCT/FR1998/002384 patent/WO1999025363A1/fr not_active Ceased
- 1998-11-09 CN CNB988130947A patent/CN1243540C/zh not_active Expired - Fee Related
- 1998-11-09 EP EP98954538A patent/EP1030671A1/fr not_active Withdrawn
- 1998-11-09 JP JP2000520796A patent/JP2001523642A/ja not_active Withdrawn
- 1998-11-09 BR BR9814035-3A patent/BR9814035A/pt not_active Application Discontinuation
- 1998-11-09 ID IDW20000860A patent/ID24933A/id unknown
- 1998-11-09 KR KR1020007005231A patent/KR100599350B1/ko not_active Expired - Fee Related
- 1998-11-09 IL IL13612298A patent/IL136122A0/xx not_active IP Right Cessation
- 1998-11-09 EA EA200000412A patent/EA003255B1/ru not_active IP Right Cessation
- 1998-11-09 EE EEP200000290A patent/EE04235B1/xx not_active IP Right Cessation
- 1998-11-09 NZ NZ504420A patent/NZ504420A/en unknown
- 1998-11-09 CA CA002309966A patent/CA2309966A1/fr not_active Abandoned
- 1998-11-09 SK SK711-2000A patent/SK286040B6/sk unknown
- 1998-11-09 AU AU11609/99A patent/AU743228B2/en not_active Ceased
- 1998-11-09 HU HU0100098A patent/HUP0100098A3/hu unknown
- 1998-11-09 PL PL98340500A patent/PL194597B1/pl not_active IP Right Cessation
- 1998-11-11 DZ DZ980259A patent/DZ2649A1/fr active
- 1998-11-12 UY UY25247A patent/UY25247A1/es not_active IP Right Cessation
- 1998-11-14 SA SA98190747A patent/SA98190747B1/ar unknown
- 1998-11-14 MY MYPI98005180A patent/MY120461A/en unknown
2000
- 2000-05-09 IS IS5482A patent/IS5482A/is unknown
- 2000-05-11 BG BG104428A patent/BG64819B1/bg unknown
- 2000-05-11 NO NO20002450A patent/NO20002450L/no unknown
- 2000-05-12 OA OA1200000141A patent/OA11464A/en unknown
- 2000-05-14 IL IL136122A patent/IL136122A/en unknown

Also Published As

Publication number	Publication date
CN1285742A (zh)	2001-02-28
EP1030671A1 (fr)	2000-08-30
DZ2649A1 (fr)	2004-12-28
BR9814035A (pt)	2000-09-26
TW585766B (en)	2004-05-01
CA2309966A1 (fr)	1999-05-27
BG64819B1 (bg)	2006-05-31
UY25247A1 (es)	2001-05-31
EE200000290A (et)	2001-06-15
AU1160999A (en)	1999-06-07
KR100599350B1 (ko)	2006-07-12
OA11464A (en)	2003-11-18
CO4980891A1 (es)	2000-11-27
NZ504420A (en)	2003-08-29
PL194597B1 (pl)	2007-06-29
IL136122A (en)	2006-07-05
EA200000412A1 (ru)	2000-12-25
KR20010032099A (ko)	2001-04-16
NO20002450D0 (no)	2000-05-11
JP2001523642A (ja)	2001-11-27
EA003255B1 (ru)	2003-02-27
SA98190747B1 (ar)	2006-11-04
CN1243540C (zh)	2006-03-01
BG104428A (en)	2001-08-31
TR200001262T2 (tr)	2001-01-22
IS5482A (is)	2000-05-09
SK7112000A3 (en)	2000-10-09
EE04235B1 (et)	2004-02-16
HUP0100098A2 (hu)	2001-07-30
MY120461A (en)	2005-10-31
IL136122A0 (en)	2001-05-20
NO20002450L (no)	2000-07-14
PL340500A1 (en)	2001-02-12
WO1999025363A1 (fr)	1999-05-27
ID24933A (id)	2000-08-31
HUP0100098A3 (en)	2001-12-28
AU743228B2 (en)	2002-01-24

Publication	Publication Date	Title
RU2221563C2 (ru)	2004-01-20	Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
DE3686622T2 (de)	1993-04-01	Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
AU2004283425A1 (en)	2005-05-06	Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
US5026716A (en)	1991-06-25	Method of treatment of anxiety and anxio-depressive disorders
JP3468526B2 (ja)	2003-11-17	筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
SK286040B6 (sk)	2008-01-07	Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín
US6258807B1 (en)	2001-07-10	Method for treating pain
US6121291A (en)	2000-09-19	Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
US6544983B2 (en)	2003-04-08	Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
US20050148614A1 (en)	2005-07-07	Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
AU739466B2 (en)	2001-10-11	Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
CA2559493A1 (fr)	2005-09-22	Composition pharmaceutique combinee concue pour inhiber le declin de fonctions cognitives
CZ20001734A3 (cs)	2000-08-16	Farmaceutická kompozice a její použití
EP1161950A1 (fr)	2001-12-12	Utilisation de diazepinoindoles dans le traitement des bronchopneumonopathies chroniques obstructives
HUT73634A (en)	1996-08-28	Use of sabeluzole for preparing pharmaceutical compositions againt chronic neurodegenerative diseases
JPS6019768A (ja)	1985-01-31	メチルレバロルフアニウム塩化合物およびその製造方法並びに薬剤
FR2771007A1 (fr)	1999-05-21	Association de principes actifs pour le traitement de la demence senile du type alzheimer